comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 00:17:17 - browse：597

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Congress may force more Covid

hotspot

WSS

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Secretariat’s lessons for human medicine

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Medicare Advantage enrollment hits roughly 33.4 million

leisure time

comprehensive

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare Advantage enrollment hits roughly 33.4 million

Supreme Court strikes down use of affirmative action

Surprise medical billing ban raises prices elsewhere

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How state and local governments are sidelining science

State Dept. review finds Biden bears some blame for Afghanistan failures

WATCH: Why do our ears pop?

Wildfire smoke exposes gaps in outdoor worker protections

As AI regulations shape up, health tech startups beg for clarity

hotspot

White House drug czar issues call for 'recovery

New study raises questions about niacin and heart health

MD Anderson's Padmanee Sharma responds to research credit suit

WATCH: Why do our ears pop?

Experimental asthma app from Apple and Anthem shows promise

In 'major milestone,' FDA approves first cell therapy for solid tumors

explore

hotspot

hotspot

Wikipedia